List of Excipients in Branded Drug EMSAM

EMSAM Excipient Strategy and Commercial Opportunities in Selegiline Transdermal Delivery

Last updated: August 9, 2026

EMSAM is a selegiline transdermal system approved for major depressive disorder. Its commercial value rests on controlled delivery of selegiline through an adhesive patch, reduced first-pass metabolism, and dose-dependent management of monoamine oxidase inhibition. The main opportunity is not a simple excipient substitution. It is a technically differentiated transdermal platform that improves adhesion, skin tolerability, dose uniformity, manufacturability, or supply resilience without changing the approved delivery concept.

What is EMSAM and how does its transdermal system work?

EMSAM delivers selegiline continuously through the skin over 24 hours. The system is approved in 6 mg/24 hours, 9 mg/24 hours, and 12 mg/24 hours strengths. The 6 mg/24-hour dose does not require the dietary tyramine restrictions that apply to the higher strengths under the FDA labeling framework. The 9 mg/24-hour and 12 mg/24-hour doses require dietary restrictions because of greater MAO-A inhibition at the gastrointestinal and hepatic level [1].

Attribute	EMSAM specification
Active ingredient	Selegiline
Dosage form	Transdermal system
Approved indication	Major depressive disorder
Strengths	6, 9, and 12 mg delivered per 24 hours
Administration	One patch applied daily
Original approval	FDA approval in 2006
NDA	021336
Drug class	Monoamine oxidase inhibitor
Primary technical challenge	Consistent transdermal flux with reliable adhesion and skin tolerability
Key commercial constraint	Small antidepressant market relative to oral generic products

Selegiline is a lipophilic molecule suitable for transdermal delivery. EMSAM avoids gastrointestinal degradation and first-pass hepatic metabolism associated with oral administration. The patch also provides an opportunity to maintain a relatively stable input rate compared with intermittent oral dosing [1,2].

What excipients are used in EMSAM?

EMSAM uses a multilayer adhesive transdermal architecture. The FDA label identifies the system as containing selegiline, an acrylic adhesive, and a silicone adhesive. The product also includes a polyester backing layer and a release liner that are removed before application [1].

The principal material categories are:

Component	Function	Commercial relevance
Selegiline-containing adhesive matrix	Holds and releases the drug	Controls drug loading, flux, and residual drug
Acrylic adhesive	Provides adhesion and may contribute to drug solubilization	Affects wear time, irritation, and release kinetics
Silicone adhesive	Provides skin contact and adhesion	Can improve removability and compatibility with lipophilic drugs
Polyester backing	Protects the matrix from the environment	Controls moisture transmission and mechanical integrity
Release liner	Protects the adhesive before use	Must remove cleanly without disturbing the matrix

The label does not create a broad opportunity to substitute any pharmaceutical excipient. In a transdermal system, the adhesive is part of the drug-delivery mechanism. A change can affect drug diffusion, crystallization, residual drug, adhesion, skin permeation, extractables, and dose delivery. FDA guidance treats transdermal systems as combination products in which the device and drug functions must be evaluated together [3].

How should an excipient strategy for EMSAM be designed?

The strongest strategy is to treat the adhesive matrix as a critical quality attribute rather than as a conventional inactive ingredient.

Control selegiline solubility and crystallization

Selegiline must remain uniformly distributed in the adhesive matrix throughout manufacturing, storage, and use. Crystallization can reduce the available dissolved fraction and produce patch-to-patch variability. Formulators should screen:

• Acrylic and silicone adhesive grades
• Drug-to-polymer ratios
• Tackifiers and plasticizers
• Solubilizers compatible with skin exposure
• Residual solvents
• Moisture sensitivity
• Storage temperature and humidity effects

A successful formulation should maintain chemical stability and physical uniformity at the highest commercial drug load while preserving the release profile for all three strengths.

Optimize skin flux without creating dose dumping

Increasing permeation is not automatically beneficial. Excessive flux can increase adverse effects and may alter the pharmacokinetic profile. The commercial objective is controlled, reproducible delivery rather than the highest possible permeation rate.

Useful formulation levers include:

• Adhesive polarity
• Polymer free volume
• Drug activity within the matrix
• Occlusivity of the backing layer
• Skin-contact pressure
• Patch surface area
• Permeation enhancers
• Crystallization inhibitors

Permeation enhancers create a high regulatory burden because they can change skin irritation, systemic exposure, and local tolerability. A lower-risk product may use adhesive and backing-layer optimization before introducing a new enhancer.

Improve adhesion and reduce skin reactions

Adhesion is a major commercial weakness for many transdermal products. EMSAM users apply the patch daily, so edge lift, sweat-related failure, hair interference, residue, and irritation directly affect persistence and perceived efficacy.

Potential excipient and material opportunities include:

• Silicone-acrylic hybrid adhesive systems
• Lower-irritancy acrylic polymers
• Adhesive systems with better adhesion under perspiration
• Reduced-residue formulations
• Hypoallergenic liner treatments
• Perimeter adhesive designs
• Backing films with better conformability
• Formulations that reduce repeated-site irritation

The product must preserve drug release after exposure to heat, exercise, bathing, and normal skin movement.

What formulations are protected by EMSAM’s product architecture?

EMSAM’s relevant technical protection is likely concentrated in the transdermal system rather than in selegiline itself. Potentially protectable subject matter includes:

1. Selegiline-containing adhesive matrices.
2. Specific acrylic and silicone adhesive combinations.
3. Drug loading and delivery-rate ranges.
4. Layered patch structures.
5. Backing and release-liner configurations.
6. Methods for treating depression with selegiline through the skin.
7. Manufacturing processes that produce uniform drug distribution.
8. Packaging systems that limit solvent loss or drug degradation.

Patent protection for these categories depends on claim scope, prosecution history, terminal disclaimers, maintenance fees, and jurisdiction. A commercial party should not assume that an expired composition patent eliminates freedom-to-operate risk for a particular adhesive system, manufacturing process, or method-of-use claim.

When does EMSAM lose exclusivity?

EMSAM lost the practical protection associated with its original FDA marketing exclusivity years ago. The product was approved in 2006, and the three-year exclusivity period applicable to a new dosage form would have expired no later than 2009, subject to the specific FDA exclusivity record [1,4].

The relevant exclusivity categories are:

Protection	EMSAM position
New chemical entity exclusivity	Not applicable to selegiline, an established active ingredient
New dosage form or new clinical investigation exclusivity	Historical protection associated with the transdermal product
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Must be confirmed from the FDA Orange Book and exclusivity records
Patent exclusivity	Historical patents may have covered the patch, formulation, or use
Current generic barrier	Primarily technical, regulatory, supply-chain, and market-based

The FDA Orange Book should be used to determine whether any patent is currently listed against the reference product and whether a listed patent has expired or been delisted [4]. Historical EMSAM patent records are more relevant to litigation analysis than to a current entry strategy unless a surviving patent claim remains enforceable.

What is the Orange Book status of EMSAM?

The Orange Book identifies EMSAM as the reference product for selegiline transdermal system regulatory purposes. An ANDA applicant must address listed patents through certification under section viii, Paragraph IV, or another applicable pathway [4].

For a generic transdermal product, the regulatory challenge is more demanding than demonstrating an equivalent tablet or capsule. FDA review may focus on:

• Same active ingredient
• Same route of administration
• Same dosage form
• Equivalent strength
• Comparable delivery performance
• Adhesion performance
• In vitro release
• Residual drug content
• Stability
• Product quality
• Labeling requirements

A prospective applicant must evaluate whether the product can rely on an ANDA or whether formulation differences require a 505(b)(2) application. A materially different patch design, new permeation enhancer, altered delivery profile, or new clinical positioning may increase the likelihood of a 505(b)(2) pathway.

Which companies are challenging or competing with EMSAM?

The competitive landscape has three segments:

Generic selegiline transdermal systems

Generic manufacturers have the clearest commercial opportunity because selegiline is an established active ingredient and transdermal delivery has already been approved. Historical generic activity has included Mylan, which was associated with the commercial supply of selegiline transdermal products. Current marketing status, discontinued products, and active ANDAs should be verified in FDA product databases and current commercial listings.

Oral selegiline products

Oral selegiline products compete on price and familiarity but do not provide the same controlled transdermal delivery. Oral products also have different tolerability, dosing, and interaction considerations. A low-cost oral generic can limit the price premium available to a patch.

Other antidepressant delivery systems

EMSAM competes indirectly with oral SSRIs, SNRIs, atypical antidepressants, and newer branded therapies. Its differentiated position is most relevant for patients who need a nonoral option, have adherence challenges, or have experienced intolerance or inadequate response with other agents.

What commercial opportunities exist for EMSAM excipients?

The strongest opportunities are platform and supply-chain opportunities rather than broad new indications.

Excipient and adhesive replacement

A supplier could develop a drop-in or near-drop-in adhesive system with:

• Equivalent or improved adhesion
• Lower skin irritation
• Reduced residual drug
• Improved shelf stability
• Lower extractables and leachables
• Better availability from multiple manufacturing sites
• Reduced dependence on a single proprietary adhesive grade

The regulatory burden is lower when the replacement preserves the product’s key performance characteristics, although the change may still require comparative release, adhesion, stability, and clinical or pharmacokinetic data.

Improved high-dose patch technology

The 9 mg/24-hour and 12 mg/24-hour systems have greater commercial value if a formulation can maintain delivery while reducing irritation or improving wear time. A formulation that reduces dose variability could support a differentiated 505(b)(2) product, but it would need a clear clinical or patient-use benefit.

Smaller and more discreet patches

Reducing patch size can improve acceptability, particularly if the same delivery rate is achieved through better flux control. The main risks are increased local drug concentration, irritation, and manufacturing variability.

Long-wear systems

A patch lasting more than 24 hours could improve adherence, but it would change the product’s use pattern and exposure profile. The development path would likely require pharmacokinetic and clinical bridging rather than a straightforward generic approach.

Combination delivery

A combination patch with another antidepressant or symptom-targeting agent would be a new product concept. It would face substantial formulation, clinical, and intellectual-property barriers and would not be a conventional excipient opportunity.

What manufacturing and intellectual-property barriers affect EMSAM?

Manufacturing barriers include uniform coating, control of adhesive rheology, solvent removal, die cutting, drug crystallization, and patch-to-patch delivery consistency. Selegiline’s volatility and chemical sensitivity must also be evaluated during coating, drying, packaging, and storage.

The main intellectual-property risks are:

• Residual formulation patents
• Manufacturing-process patents
• Adhesive composition patents
• Permeation-enhancer claims
• Patch geometry claims
• Method-of-use claims
• Packaging and stability claims
• Patent rights in markets outside the United States

A generic applicant should conduct a claim chart against the reference product, historical EMSAM patents, adhesive supplier patents, and third-party transdermal technologies. A Paragraph IV challenge may be commercially rational only if the remaining patent claims are narrow, vulnerable, or close to expiration. The limited size of the antidepressant patch market can make litigation economics unfavorable even when the legal position is strong.

What patent litigation and settlement issues affect EMSAM?

Historical patent litigation may have involved generic challenges to transdermal selegiline patents. Any analysis of a prior settlement should distinguish:

• Patent expiration date
• Earliest authorized generic entry date
• Royalty provisions
• Product-specific restrictions
• Supply or licensing rights
• Acceleration clauses
• Antitrust risk
• Whether the agreement remains commercially relevant

A historical settlement does not by itself establish a current market barrier. The operative questions are whether the covered patents remain enforceable, whether the settling company still has entry rights, and whether the agreement contains restrictions that survive patent expiration. These issues require review of the underlying court docket and settlement documents rather than reliance on product listings alone.

How strong is the EMSAM patent estate?

The estate is strategically weaker than a new chemical entity estate because selegiline is old and the principal innovation is delivery technology. Its strength depends on the surviving claims, not on the existence of numerous historical filings.

Patent-estate dimension	Assessment
Active-ingredient protection	Weak or expired
Transdermal dosage-form protection	Historically important
Adhesive and matrix claims	Potentially relevant to formulation freedom to operate
Method-of-use protection	Potentially relevant but limited by patent age and claim scope
Manufacturing protection	Can create practical barriers if narrowly drafted
Regulatory exclusivity	Expired
Generic substitution risk	High if a technically acceptable ANDA is approved
Reformulation opportunity	Moderate, especially for adhesion and tolerability

The strongest defensible product would combine a clinically meaningful benefit with a differentiated formulation, such as improved adhesion, reduced irritation, or a smaller patch. A formulation that merely changes an adhesive supplier without measurable patient benefit would have limited pricing power.

What generic launch scenarios exist for EMSAM?

Three launch scenarios are commercially plausible:

1. A conventional generic patch enters at a discount and competes primarily on availability and price.
2. A differentiated 505(b)(2) patch launches with improved adhesion, reduced irritation, or a modified wear profile.
3. A branded or authorized-generic arrangement uses existing manufacturing capacity and competes through reliable supply rather than formulation innovation.

The market is unlikely to support multiple high-cost entrants unless prescriptions expand or a manufacturer captures a meaningful supply advantage. The primary launch risk is not only patent litigation. It is the cost of demonstrating transdermal equivalence in a small market.

How does EMSAM compare with oral selegiline and other antidepressant products?

Criterion	EMSAM	Oral selegiline	Standard oral antidepressants
Administration	Daily patch	Oral dosing	Oral dosing
First-pass avoidance	Yes	No	Usually no
Adherence differentiation	Visible daily system	Conventional	Conventional
Formulation complexity	High	Lower	Usually lower
Manufacturing cost	Higher	Lower	Lower
Generic substitution	Technically difficult	Easier	Generally easier
Main commercial advantage	Nonoral controlled delivery	Low cost and familiarity	Broad prescribing base
Main commercial risk	Small market and patch tolerability	Limited differentiation	Intense generic competition

Key Takeaways

• EMSAM is a selegiline transdermal system approved in 6, 9, and 12 mg/24-hour strengths.
• Its excipient strategy centers on acrylic and silicone adhesive systems, backing materials, release liners, drug uniformity, and controlled skin flux.
• The most attractive formulation opportunities involve adhesion, skin tolerability, crystallization control, smaller patch size, and supply-chain resilience.
• Original FDA exclusivity has expired, and current entry risk depends on the Orange Book record, surviving patents, ANDA requirements, and technical equivalence.
• The active ingredient has limited patent value because selegiline is an established compound.
• A conventional generic faces high technical development costs relative to the likely market size.
• A differentiated 505(b)(2) product may have greater commercial potential if it demonstrates a measurable patient benefit.
• Manufacturing know-how, adhesive compatibility, coating control, and packaging may create more practical barriers than active-ingredient patents.

FAQs About EMSAM Excipient and Commercial Strategy

Can a manufacturer replace the EMSAM adhesive without changing the regulatory pathway?

Yes, but the replacement must preserve critical product performance, including drug release, adhesion, stability, residual drug, and skin tolerability. A material change can require substantial comparative data and may affect the appropriate FDA application pathway.

Is selegiline transdermal system suitable for an authorized generic strategy?

Yes. An authorized generic could use the reference product’s established formulation and manufacturing platform, reducing development risk. The commercial value would depend on market size, supply reliability, and the ability to obtain favorable manufacturing economics.

Could a new EMSAM patch qualify for 505(b)(2) approval?

Potentially. A new patch with a modified delivery profile, patch size, adhesive system, or wear duration could require a 505(b)(2) application if it relies partly on the existing selegiline transdermal product while introducing clinically relevant differences.

Are permeation enhancers a strong patent opportunity for EMSAM?

They can be, but the opportunity carries substantial technical and regulatory risk. A permeation enhancer must improve delivery without creating excessive exposure, irritation, dose dumping, or stability problems. The strongest claims would link the enhancer to a defined performance or clinical advantage.

What is the most defensible commercial differentiation for a new selegiline patch?

Improved adhesion with lower skin irritation is likely more defensible than a simple price-based generic strategy. A smaller, more discreet patch or a validated longer-wear system could also support differentiation if the product demonstrates equivalent safety and controlled exposure.

References

1. U.S. Food and Drug Administration. (2006). EMSAM (selegiline transdermal system) prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: EMSAM, selegiline transdermal system.
3. U.S. Food and Drug Administration. (2019). Transdermal and topical delivery systems: Product development and quality considerations.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.